Ocular Therapeutix™ to Participate in March Investor Conferences
Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations
Reassessing Ocular Therapeutix (OCUL) After Sharp Pullback And Conflicting Valuation Signals [Yahoo! Finance]
Ocular Therapeutix (NASDAQ:OCUL) had its price target lowered by analysts at Needham & Company LLC from $20.00 to $18.00. They now have a "buy" rating on the stock.
Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses